Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
POMPANO BEACH, Fla., April 1, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 – BioStem Technologies, Inc.
BioStem Technologies: Building On Advanced Wound Care Needs
BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing. Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing 1,702%, driven by robust product adoption and strategic partnerships. Despite operational success, BioStem's stock remains undervalued; a one-year price target of $17.22 reflects a 60.13% increase from its current price.
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
Study comparing BioStem's proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, FL, February 24, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
POMPANO BEACH, Fla., January 13, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024.
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies CEO to Present at Biotech Showcase 2025
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem's commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 – PRISM MediaWire – BioStem Technologies Inc.
Long-Term, BioStem Technologies Still A Promising Growth Stock
BioStem Technologies has experienced significant price volatility, driven by positive news and uplisting plans, but recent profit-taking has caused a pullback. Q3 earnings report showed impressive growth with record revenue and positive net income, reinforcing the company's strong financial performance. Future growth looks promising with a robust product pipeline and potential Nasdaq uplisting, supporting a one-year price target of $27.88.
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer Michael Fortunato - Chief Financial Officer Conference Call Participants Ernest Watts - Watts Associates Operator Thank you for standing by. My name is Rebecca and I will be your conference operator today.
